Contrasting Actinium Pharmaceuticals (NYSE:ATNM) and Cytokinetics (NASDAQ:CYTK)Defense World · 3 days ago
Cytokinetics to Announce Third Quarter Results on November 4, 2026GlobeNewsWire · 3 days ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · 5 days ago
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Zacks Investment Research · 6 days ago
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic CardiomyopathyGlobeNewsWire · 6 days ago
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)Defense World · Oct 14, 2026Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.63 | -$1.50 | Beat |
| May 5, 2026 | -$1.67 | -$1.67 | Beat |
| Feb 24, 2026 | -$1.48 | -$1.50 | Miss |
| Nov 5, 2025 | -$1.59 | -$2.55 | Miss |
| Aug 7, 2025 | -$1.34 | -$1.12 | Beat |
| May 6, 2025 | -$1.41 | -$1.36 | Beat |